STIs Surge to Record Highs in Europe, Prompting Urgent Health Concerns

Across Europe, sexually transmitted infections (STIs) are climbing at an alarming rate, with gonorrhea and syphilis reaching record highs, according to the latest data from the European Centre for Disease Prevention and Control (ECDC). The surge in cases has triggered urgent calls for increased public awareness, enhanced prevention strategies, and improved access to testing and treatment. The ECDC's recent Annual Epidemiological Reports highlight a concerning trend that demands immediate attention to curb further transmission and mitigate the impact on public health.

Gonorrhea Rates Skyrocket

Gonorrhea, in particular, has seen a dramatic increase. In 2023, nearly 100,000 confirmed cases were reported in EU/EEA countries, marking a 31% jump compared to 2022 and a staggering 321% rise since 2014. This represents the highest recorded rate in Europe since the ECDC began monitoring STIs in 2009. The increase spans various age groups and demographics, with women aged 20 to 24 experiencing the steepest rise at 46%. Men who have sex with men (MSM) account for a significant portion, representing 58% of gonorrhea cases. Untreated gonorrhea can lead to severe health complications, including pelvic inflammatory disease and infertility in both men and women.

Adding to the concern is the growing threat of antimicrobial resistance (AMR) in gonorrhea. Some strains are becoming resistant to azithromycin, a common antibiotic used in combination with ceftriaxone for treatment. Multidrug-resistant and extensively drug-resistant gonorrhea isolates have also been detected, raising fears about the future effectiveness of current treatments.

Syphilis Cases Double Since 2014

Syphilis is another STI exhibiting a worrying upward trend. In 2023, 41,051 confirmed cases were reported across 29 EU/EEA countries, a 13% increase from 2022 and a doubling since 2014. Syphilis is disproportionately affecting men, with seven men diagnosed for every woman. The highest rates are observed among men aged 25 to 34, with MSM accounting for 72% of cases. However, rates are also increasing among women of all age groups. Untreated syphilis can cause long-term complications affecting the heart and brain. There has also been an increase in congenital syphilis, with 78 confirmed cases reported in 2023, which is caused by transmission from mother to fetus.

Chlamydia Remains Prevalent

While the rate of increase in chlamydia notifications slowed in 2023, it remains the most frequently reported bacterial STI in Europe. Over 230,000 cases were reported across EU/EEA countries in 2023, representing a 13% increase since 2014. Chlamydia continues to disproportionately affect young people, with the highest rates among women aged 20 to 24.

Factors Contributing to the Rise

Several factors are believed to be driving the surge in STIs across Europe. Increased testing and screening, particularly among at-risk populations, likely contribute to the higher numbers of reported cases. However, changes in sexual behavior, such as decreased condom use and an increase in the number of sexual partners, are also significant factors.

The availability of HIV pre-exposure prophylaxis (PrEP) may also play a role. PrEP is a preventive medicine that protects against HIV infection. Some men who take PrEP may choose not to use condoms, increasing their risk of contracting other STIs.

Public Health Response and Prevention

In response to the rising STI rates, health authorities are emphasizing the importance of proactive measures. The ECDC stresses that consistent condom use during vaginal, anal, and oral sex is crucial for prevention. Open and honest communication about sexual health with partners can also help reduce the risk of STI transmission.

The ECDC and WHO Europe are urging increased public awareness campaigns, expanded access to testing and treatment services, and efforts to combat the stigma associated with STIs. Early detection and treatment are essential to prevent further transmission and potential complications. Regular STI testing is recommended for sexually active individuals, especially those with new or multiple partners, as many infections can be asymptomatic.

Researchers are also exploring new prevention methods, including vaccines. An investigational vaccine for Neisseria gonorrhoeae, the bacteria that causes gonorrhea, received Fast Track designation from the U.S. Food and Drug Administration in 2023. Studies have also reported the potential effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine in preventing gonorrhea infections.

A Call for Concerted Action

The escalating rates of STIs in Europe represent a significant public health challenge. The concerning trends in gonorrhea and syphilis, coupled with the continued prevalence of chlamydia, demand urgent and concerted action. By increasing public awareness, promoting safer sexual practices, expanding access to testing and treatment, and investing in research and development of new prevention tools, Europe can work towards curbing the spread of STIs and protecting the health of its citizens. The need for a comprehensive and coordinated approach is more critical than ever to reverse these alarming trends and safeguard sexual health across the region.